Corticosteroid osteoporosis.

Area of Science:

• Endocrinology
• Rheumatology
• Pharmacology

Background:

• Corticosteroids are essential for managing chronic inflammatory diseases.
• High-dose corticosteroid use leads to rapid bone loss, particularly within 12-24 months.
• Corticosteroid-induced bone loss necessitates distinct preventive and treatment strategies.

Purpose of the Study:

• To outline therapeutic strategies for preventing and treating bone loss in patients on corticosteroids.
• To emphasize the importance of calcium intake and managing osteoporosis risk factors.
• To guide pharmacological interventions based on bone density assessments.

Main Methods:

• Review of therapeutic approaches for corticosteroid-induced bone loss.
• Recommendations for calcium intake and management of contributing factors.
• Guidelines for prophylactic and treatment regimens including bisphosphonates and vitamin D metabolites.

Main Results:

• Prophylactic bisphosphonates and/or active vitamin D metabolites (alphacalcidol, calcitriol) are recommended for patients starting high-dose, long-term corticosteroids.
• Treatment with bisphosphonates and vitamin D metabolites can improve bone density in patients on chronic corticosteroids.
• Estrogen replacement therapy is appropriate for postmenopausal women on chronic corticosteroids.

Conclusions:

• Early intervention is crucial to mitigate corticosteroid-related bone loss.
• Personalized treatment plans, including bone density monitoring and medication review, are essential.
• Pharmacological treatments like bisphosphonates and vitamin D are effective in managing corticosteroid-induced osteoporosis.